{
    "clinical_study": {
        "@rank": "158086", 
        "arm_group": [
            {
                "arm_group_label": "Dupilumab SAR231893 (REGN668)", 
                "arm_group_type": "Experimental", 
                "description": "Dupilumab loading Dose (x2), followed by every week injection in combination with intranasal mometasone furoate spray for 16 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo loading Dose (x2), followed by placebo dose every week in combination with intranasal mometasone furoate spray for 16 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To evaluate the efficacy of dupilumab in the treatment of bilateral Nasal Polyposis (NP) by\n      assessment of the endoscopic nasal polyp score in comparison to placebo.\n\n      Secondary Objectives:\n\n      To evaluate effect of dupilumab with regards to:\n\n        -  symptoms of sinusitis\n\n        -  sinus CT scan\n\n        -  nasal polyp score in the sub-group of patients with co-morbid asthma\n\n        -  Safety and tolerability"
        }, 
        "brief_title": "An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Nasal Polyps", 
        "condition_browse": {
            "mesh_term": [
                "Nasal Polyps", 
                "Sinusitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Screening period (4 weeks) + Randomized Treatment Period (16 weeks)+ Post-Treatment Period\n      (16 weeks) = 36 weeks.\n\n      To ensure at least 28 patients with co-morbid asthma needed for subgroup analysis,\n      recruitment of NP patients without co-morbid asthma will stop when approximately 28 patients\n      without asthma are randomized."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Patients with:\n\n          -  A minimum bilateral nasal polyp score of 5 out of a maximum score of 8 (with a\n             unilateral score of at least 2 for each nostril) despite completion of a prior INCS\n             treatment for at least 8 weeks before screening.\n\n          -  Presence of at least two of the following symptoms prior to screening: nasal\n             blockade/obstruction/congestion or nasal discharge (anterior/posterior nasal drip);\n             facial pain/pressure; reduction or loss of smell.\n\n        Exclusion criteria:\n\n          -  Patients <18 or >65 years of age.\n\n          -  Sinonasal outcome test (SNOT22) <7.\n\n          -  Patients who have taken other investigational drugs or prohibited therapy for this\n             study within 2 months before screening or 5 half-lives, whichever is longer:\n\n          -  who have required a burst of systemic corticosteroids within the 2 months before\n             screening or are scheduled to receive systemic corticosteroids during the study\n             period for another condition\n\n          -  who have required intranasal corticosteroid drops within 1 month prior to screening\n             Monoclonal antibody (mAB) and immunosuppressive treatment; Anti-immunoglobulin E\n             (IgE) therapy (omalizumab) within 130 days of Visit 1; Leukotriene antagonists /\n             modifiers unless patient is on a continuous treatment for at least 30 days prior to\n             Visit 1.\n\n          -  Patients who have undergone any nasal surgery (including polypectomy) within 6 months\n             before screening or have had more than 5 sinonasal surgeries in the past of which\n             maximal 2 were surgeries changing the lateral wall structure of the nose.\n\n          -  Patients with asthma having:\n\n          -  Forced Expiratory Volume (FEV1) \u2264 60%, or\n\n          -  an asthma exacerbation requiring systemic (oral and/or parenteral) steroid treatment\n             or hospitalization for >24h for treatment of asthma, within 3 months prior to\n             screening or are on a dose of greater than 1000 \u03bcg fluticasone or an equivalent\n             inhaled corticosteroids.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01920893", 
            "org_study_id": "ACT12340", 
            "secondary_id": [
                "2013-001803-35", 
                "U1111-1130-6475"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Dupilumab SAR231893 (REGN668)", 
                "description": "Pharmaceutical form:solution Route of administration: subcutaneous", 
                "intervention_name": "dupilumab SAR231893 (REGN668)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Pharmaceutical form:solution Route of administration: subcutaneous", 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Dupilumab SAR231893 (REGN668)", 
                    "Placebo"
                ], 
                "description": "Pharmaceutical form:suspension Route of administration: intranasal", 
                "intervention_name": "mometasone furoate nasal spray", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Mometasone furoate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Rolling Hills Estates", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90274"
                    }, 
                    "name": "Investigational Site Number 840014"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80230"
                    }, 
                    "name": "Investigational Site Number 840015"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Investigational Site Number 840013"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lake Oswego", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97035"
                    }, 
                    "name": "Investigational Site Number 840002"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburg", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Investigational Site Number 840009"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }, 
                    "name": "Investigational Site Number 056001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3500"
                    }, 
                    "name": "Investigational Site Number 056002"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Investigational Site Number 724001"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Faitanar", 
                        "country": "Spain", 
                        "zip": "46014"
                    }, 
                    "name": "Investigational Site Number 724003"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hospitalet De Llobregat", 
                        "country": "Spain", 
                        "zip": "08907"
                    }, 
                    "name": "Investigational Site Number 724002"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jerez De La Frontera", 
                        "country": "Spain", 
                        "zip": "11407"
                    }, 
                    "name": "Investigational Site Number 724005"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Investigational Site Number 724004"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "14186"
                    }, 
                    "name": "Investigational Site Number 752001"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "171 76"
                    }, 
                    "name": "Investigational Site Number 752002"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Spain", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in endoscopic Nasal Polyp Score (NPS)", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01920893"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in NPS in sub-group of co-morbid asthma", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "Change from baseline in patient reported symptoms of sinusitis", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "Change from baseline in nasal peak inspiratory flow", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "Change from baseline in smell test", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "Change from baseline in CT scan", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "Time to first response in NPS", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}